Head-to-head evidence
Hemay005 vs roflumilast
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: PDE4 · full Psoriasis pipeline
Hemay005
Developed by Tianjin Hemay Pharmaceutical
NCT04839328 · Phase 3 · completed
The study randomized 306 participants to Hemay005 or placebo, with participants masked to treatment, and used the clinical PASI75 response as its primary endpoint. Because no comparative results or statistical analysis are posted, the primary endpoint cannot be assessed.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
roflumilast · Zoryve
Marketed by Arcutis Biotherapeutics
NCT06648772 · Phase 3 · completed
The study randomly assigned 190 participants to roflumilast cream or vehicle cream and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was a clinical psoriasis severity measure, but whether that endpoint was met cannot be determined because results are not available.
Next expected readout: July 2027 · NCT07725822 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Hemay005's landscape · roflumilast's landscape